The Fresenius company, the makers of the dialysis drug GranuFlo, have reached a settlement in their litigation against many lawsuits filed against the company.
Patients that filed lawsuits claiming that GranuFlo led to serious and deadly side effects have reached a $250 million dollar settlement with the company. The settlement is “in principle.” This basically means that the company agreed to the settlement without admitting to any defect in their product.
The plaintiffs in the GranuFlo lawsuits allege that the use of the product during hemodialysis led to severe heart problems and sudden death in some patients. The plaintiffs further charged that Fresenius did not provide adequate instructions for use or warnings about their products.
An internal memo was circulated within the Fresenius Company’s dialysis centers. The memo voiced concerns about the potential danger of the product GranuFlo. The memo, which was dated in 2011, urged clinic personnel to used increased caution when mixing GranuFlo and Naturalyte for dialysis treatments.
However, that same memo never made it to hundreds of other non-Fresenius clinics. This left patients of these clinics at risk of possible mixing errors.
The concern with the Fresenius products stems from the fact that the unique formulations required different mixing instructions. Mixing the products incorrectly could lead to a serious increase in levels of bicarbonate in the blood. This leads to a serious condition called metabolic alkalosis. This condition increases a person’s risk for heart arrythmias, decreased blood pressure, and heart attack.
As patients began being injured or even losing their life as a result of the use of these products, the patients and families began filing lawsuits. More than 10,000 lawsuits have been filed against Fresenius.
If you have suffered from complications or injury due to the use of GranuFlo, you may be entitled to compensation. Contact the law offices of John Foy & Associates. Our “Strong Arm” attorneys will help you get the compensation you deserve. Contact us today.